Optimization of a Moving Averages Program Using a Simulated Annealing Algorithm: The Goal is to Monitor the Process Not the Patients

被引:74
作者
Ng, David [1 ]
Polito, Frank A. [1 ]
Cervinski, Mark A. [1 ,2 ]
机构
[1] Dartmouth Hitchcock Med Ctr, Dept Pathol & Lab Med, Lebanon, NH 03766 USA
[2] Geisel Sch Med Dartmouth, Hanover, NH USA
关键词
LABORATORY QUALITY-CONTROL; IMPLEMENTATION; COMMUTABILITY; PERFORMANCE;
D O I
10.1373/clinchem.2016.257055
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
BACKGROUND: The patient moving average (MA) is a QC strategy using the mean patient result to continuously monitor assay performance. Developing sensitive MA protocols that rapidly detect systematic error (SE) is challenging. We compare MA protocols established using a previously published report as a guide and demonstrate the use of a simulated annealing (SA) algorithm to optimize MA protocol performance. METHODS: Using 400 days of patient data, we developed MA protocols for 23 assays. MA protocols developed using a previously published report and our SA algorithm were compared using the average number of patient samples affected until error detection (ANP(ed)). RESULTS: Comparison of the strategies demonstrated that protocols developed using the SA algorithm generally proved superior. Some analytes such as total protein showed considerable improvement, with positive SE equal to 0.8 g/dL detected with an ANP(ed) of 135 samples using the previously published method whereas the SA algorithm detected this SE with an ANP(ed) of 18. Not all analytes demonstrated similar improvement with the SA algorithm. Phosphorus, for instance, demonstrated only minor improvements, with a positive SE of 0.9 mg/dL detected with an ANPed of 34 using the previously published method vs an ANP(ed) of 29 using the SA algorithm. We also demonstrate an example of SE detection in a live environment using the SA algorithm derived MA protocols. CONCLUSIONS: The SA algorithm developed MA protocols are currently in use in our laboratory and they rapidly detect SE, reducing the number of samples requiring correction and improving patient safety. (C) 2016 American Association for Clinical Chemistry
引用
收藏
页码:1361 / 1371
页数:11
相关论文
共 15 条
[1]   A mechanism-based way to evaluate commutability of control materials for enzymatic measurements. The example of gamma-glutamyltransferase [J].
Carobene, Anna ;
Guerra, Elena ;
Ceriotti, Ferruccio .
CLINICA CHIMICA ACTA, 2013, 424 :153-158
[2]   ASSESSMENT OF AVERAGE OF NORMALS QUALITY-CONTROL PROCEDURES AND GUIDELINES FOR IMPLEMENTATION [J].
CEMBROWSKI, GS ;
CHANDLER, EP ;
WESTGARD, JO .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1984, 81 (04) :492-499
[3]   Changing the paradigm of laboratory quality control through implementation of real-time test results monitoring: For patients by patients [J].
Fleming, James K. ;
Katayev, Alexander .
CLINICAL BIOCHEMISTRY, 2015, 48 (7-8) :508-513
[4]  
HOFFMANN RG, 1965, AM J CLIN PATHOL, V43, P134
[5]   The exponentially weighted moving average (EWMA) rule compared with traditionally used quality control rules [J].
Linnet, K .
CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2006, 44 (04) :396-399
[6]   Commutability Limitations Influence Quality Control Results with Different Reagent Lots [J].
Miller, W. Greg ;
Erek, Aybala ;
Cunningham, Tina D. ;
Oladipo, Olajumoke ;
Scott, Mitchell G. ;
Johnson, Robert E. .
CLINICAL CHEMISTRY, 2011, 57 (01) :76-83
[7]  
Parvin CA, 1997, CLIN CHEM, V43, P2149
[8]   Assessing the Impact of the Frequency of Quality Control Testing on the Quality of Reported Patient Results [J].
Parvin, Curtis A. .
CLINICAL CHEMISTRY, 2008, 54 (12) :2049-2054
[9]  
REED AH, 1970, CLIN CHEM, V16, P129
[10]  
REJ R, 1984, TALANTA, V31, P851, DOI 10.1016/0039-9140(84)80214-3